Literature DB >> 18535868

Global protein-expression analysis of bone and soft tissue sarcomas.

Akira Kawai1, Tadashi Kondo, Yoshiyuki Suehara, Kazutaka Kikuta, Setsuo Hirohashi.   

Abstract

UNLABELLED: Analysis of global protein expression, an approach known as expression proteomics, can offer important clues for understanding tumor biology that cannot be obtained by other approaches (e.g., genome or transcriptome analysis). Using two-dimensional difference gel electrophoresis (2D-DIGE) and mass spectrometry, we performed global protein expression studies of bone and soft tissue sarcomas to develop novel diagnostic and therapeutic biomarkers and allow molecular classification of the tumors. Among 1500 protein variants identified in the two-dimensional gel, 67 proteins correctly distinguished the eight subtypes of 99 histologically classified soft tissue sarcomas. Hierarchical clustering demonstrated leiomyosarcoma and MFH shared a similar protein expression profile, and clear cell sarcoma, synovial sarcoma, and MPNST could be grouped according to their protein expression patterns. Pleomorphic leiomyosarcoma and MFH showed similar tropomyosin isoform expression patterns. Patients with gastrointestinal stromal tumors expressing pfetin protein had better survival than those whose tumors lacked it. We identified 10 protein spots associated with the chemosensitivity of osteosarcoma to preoperative chemotherapy. These 10 spots could be new diagnostic and prognostic markers for osteosarcoma and new therapeutic targets for the disease. Proteomic analysis using 2D-DIGE provides novel information on the biology of bone and soft tissue sarcomas that could be used to diagnosis and treat these tumors. LEVEL OF EVIDENCE: Level II, diagnostic study. See the Guidelines for Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18535868      PMCID: PMC2493021          DOI: 10.1007/s11999-008-0330-4

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  41 in total

1.  Prosthetic knee replacement after resection of a malignant tumor of the distal part of the femur. Medium to long-term results.

Authors:  A Kawai; G F Muschler; J M Lane; J C Otis; J H Healey
Journal:  J Bone Joint Surg Am       Date:  1998-05       Impact factor: 5.284

2.  Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.

Authors:  G Bacci; S Ferrari; N Delepine; F Bertoni; P Picci; M Mercuri; P Bacchini; A Brach del Prever; A Tienghi; A Comandone; M Campanacci
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

3.  Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma.

Authors:  L Guillou; J M Coindre; F Bonichon; B B Nguyen; P Terrier; F Collin; M O Vilain; A M Mandard; V Le Doussal; A Leroux; J Jacquemier; H Duplay; X Sastre-Garau; J Costa
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

4.  Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome.

Authors:  N Baldini; K Scotlandi; G Barbanti-Bròdano; M C Manara; D Maurici; G Bacci; F Bertoni; P Picci; S Sottili; M Campanacci
Journal:  N Engl J Med       Date:  1995-11-23       Impact factor: 91.245

5.  Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics.

Authors:  Yoshiyuki Suehara; Tadashi Kondo; Kunihiko Seki; Tatsuhiro Shibata; Kiyonaga Fujii; Masahiro Gotoh; Tadashi Hasegawa; Yasuhiro Shimada; Mitsuru Sasako; Tadakazu Shimoda; Hisashi Kurosawa; Yasuo Beppu; Akira Kawai; Setsuo Hirohashi
Journal:  Clin Cancer Res       Date:  2008-03-15       Impact factor: 12.531

6.  Isolation from cochlea of a novel human intronless gene with predominant fetal expression.

Authors:  Barbara L Resendes; Sharon F Kuo; Nahid G Robertson; Anne B S Giersch; Dynio Honrubia; Osamu Ohara; Joe C Adams; Cynthia C Morton
Journal:  J Assoc Res Otolaryngol       Date:  2004-06

Review 7.  Biology and therapeutic advances for pediatric osteosarcoma.

Authors:  Neyssa Marina; Mark Gebhardt; Lisa Teot; Richard Gorlick
Journal:  Oncologist       Date:  2004

8.  Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.

Authors:  G Rosen; B Caparros; A G Huvos; C Kosloff; A Nirenberg; A Cacavio; R C Marcove; J M Lane; B Mehta; C Urban
Journal:  Cancer       Date:  1982-03-15       Impact factor: 6.860

9.  Osteosarcoma in children: long-term functional analysis.

Authors:  Per-Ulf Tunn; Peter Schmidt-Peter; Doreen Pomraenke; Peter Hohenberger
Journal:  Clin Orthop Relat Res       Date:  2004-04       Impact factor: 4.176

10.  Relation between cellular doxorubicin binding ability to nuclear DNA and histologic response to preoperative chemotherapy in patients with osteosarcoma.

Authors:  K Kusuzaki; H Takeshita; H Murata; M Hirata; S Hashiguchi; T Ashihara; Y Hirasawa
Journal:  Cancer       Date:  1998-06-15       Impact factor: 6.860

View more
  15 in total

1.  Immune and inflammatory pathways are involved in inherent bone marrow ossification.

Authors:  Umut Atakan Gurkan; Ryan Golden; Vipuil Kishore; Catherine P Riley; Jiri Adamec; Ozan Akkus
Journal:  Clin Orthop Relat Res       Date:  2012-09       Impact factor: 4.176

Review 2.  Molecular genetic studies of gene identification for osteoporosis: the 2009 update.

Authors:  Xiang-Hong Xu; Shan-Shan Dong; Yan Guo; Tie-Lin Yang; Shu-Feng Lei; Christopher J Papasian; Ming Zhao; Hong-Wen Deng
Journal:  Endocr Rev       Date:  2010-03-31       Impact factor: 19.871

Review 3.  Soft tissue sarcomas with complex genomic profiles.

Authors:  Louis Guillou; Alain Aurias
Journal:  Virchows Arch       Date:  2010-02       Impact factor: 4.064

4.  Biomarkers in Osteosarcoma.

Authors:  Colin Kong; Marc F Hansen
Journal:  Expert Opin Med Diagn       Date:  2009-01-01

5.  Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysis.

Authors:  Amalia Conti; Gemma Caballero Rodriguez; Antonella Chiechi; Rosa Maria Dégano Blazquez; Victoria Barbado; Tibor Krènacs; Chiara Novello; Laura Pazzaglia; Irene Quattrini; Licciana Zanella; Piero Picci; Enrique De Alava; Maria Serena Benassi
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

Review 6.  Proteomic analysis of soft tissue sarcoma.

Authors:  Yoshiyuki Suehara
Journal:  Int J Clin Oncol       Date:  2011-03-09       Impact factor: 3.402

7.  Comparative proteomic analysis of plasma membrane proteins between human osteosarcoma and normal osteoblastic cell lines.

Authors:  Zhiyu Zhang; Lijun Zhang; Yingqi Hua; Xiaofang Jia; Jian Li; Shuo Hu; Xia Peng; Pengyuan Yang; Mengxiong Sun; Fang Ma; Zhengdong Cai
Journal:  BMC Cancer       Date:  2010-05-14       Impact factor: 4.430

8.  Overexpression of metadherin mediates metastasis of osteosarcoma by regulating epithelial-mesenchymal transition.

Authors:  J Tang; L Shen; Q Yang; C Zhang
Journal:  Cell Prolif       Date:  2014-09-01       Impact factor: 6.831

9.  Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value.

Authors:  Elizabeth G Demicco; Genevieve M Boland; Kari J Brewer Savannah; Kristelle Lusby; Eric D Young; Davis Ingram; Kelsey L Watson; Marshall Bailey; Xiangqian Guo; Jason L Hornick; Matt van de Rijn; Wei-Lien Wang; Keila E Torres; Dina Lev; Alexander J Lazar
Journal:  Histopathology       Date:  2015-01-12       Impact factor: 5.087

10.  Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1.

Authors:  Luisa Cironi; Paolo Provero; Nicola Riggi; Michalina Janiszewska; Domizio Suva; Mario-Luca Suva; Vincent Kindler; Ivan Stamenkovic
Journal:  PLoS One       Date:  2009-11-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.